| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/BRAIN/AWY154 |
| P698 | PubMed publication ID | 29860296 |
| P50 | author | Claudio Gobbi | Q55302470 |
| Christian Barro | Q60690467 | ||
| P2093 | author name string | Giulio Disanto | |
| David Leppert | |||
| Ludwig Kappos | |||
| Jens Kuhle | |||
| Michael Amann | |||
| Cristina Granziera | |||
| Jens Wuerfel | |||
| Yvonne Naegelin | |||
| Zuzanna Michalak | |||
| Özgür Yaldizli | |||
| Katrin Parmar | |||
| Pascal Benkert | |||
| Charidimos Tsagkas | |||
| P433 | issue | 8 | |
| P304 | page(s) | 2382-2391 | |
| P577 | publication date | 2018-08-01 | |
| P1433 | published in | Brain | Q897386 |
| P1476 | title | Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis | |
| P478 | volume | 141 |
| Q89531252 | Association of intrathecal pleocytosis and IgG synthesis with axonal damage in early MS |
| Q64264326 | Blood Levels of Co-inhibitory-Receptors: A Biomarker of Disease Prognosis in Multiple Sclerosis |
| Q64970888 | Blood neurofilament light as a potential endpoint in Phase 2 studies in MS. |
| Q64064373 | Blood neurofilament light chain as a biomarker of MS disease activity and treatment response |
| Q89663884 | Blood neurofilament light levels segregate treatment effects in multiple sclerosis |
| Q60954944 | CSF Neurofilament Light Chain Levels in Primary Progressive MS: Signs of Axonal Neurodegeneration |
| Q90680799 | Combined Cerebrospinal Fluid Neurofilament Light Chain Protein and Chitinase-3 Like-1 Levels in Defining Disease Course and Prognosis in Multiple Sclerosis |
| Q91897392 | Detecting neurodegenerative pathology in multiple sclerosis before irreversible brain tissue loss sets in |
| Q92290385 | Diagnosis and Management of Progressive Multiple Sclerosis |
| Q90701124 | Dimethyl fumarate decreases neurofilament light chain in CSF and blood of treatment naïve relapsing MS patients |
| Q92375171 | Early highly effective versus escalation treatment approaches in relapsing multiple sclerosis |
| Q64122269 | Evolution of clinical trials in multiple sclerosis |
| Q90088600 | High serum neurofilament light chain normalizes after hematopoietic stem cell transplantation for MS |
| Q92904423 | Intrathecal B-cell accumulation and axonal damage distinguish MRI-based benign from aggressive onset in MS |
| Q96022717 | Lipid Mediator Profiles Predict Response to Therapy with an Oral Frankincense Extract in Relapsing-Remitting Multiple Sclerosis |
| Q64229784 | Mechanisms of Neurodegeneration and Axonal Dysfunction in Progressive Multiple Sclerosis |
| Q92212758 | Molecular biomarkers in multiple sclerosis |
| Q90621003 | Multiple sclerosis in 2018: new therapies and biomarkers |
| Q59791789 | Neurofilament Light Chain: Blood Biomarker of Neonatal Neuronal Injury |
| Q90319644 | Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis |
| Q57588817 | Neurofilaments as biomarkers in neurological disorders |
| Q90167116 | Neurofilaments in disease: what do we know? |
| Q92814294 | Neurofilaments: The C-Reactive Protein of Neurology |
| Q92709805 | Non-parametric combination analysis of multiple data types enables detection of novel regulatory mechanisms in T cells of multiple sclerosis patients |
| Q61449501 | Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis |
| Q103028221 | Plasma N-terminal tau fragment levels predict future cognitive decline and neurodegeneration in healthy elderly individuals |
| Q64067780 | Profiling individual clinical responses by high-frequency serum neurofilament assessment in MS |
| Q92802794 | Reaching an evidence-based prognosis for personalized treatment of multiple sclerosis |
| Q96950971 | Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity |
| Q60961744 | Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease |
| Q92774722 | Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study |
| Q96685857 | Serum neurofilament light chain predicts long term clinical outcomes in multiple sclerosis |
| Q89636874 | Serum neurofilament light levels in normal aging and their association with morphologic brain changes |
| Q91137193 | Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders |
| Q62652948 | Targeting progression in multiple sclerosis — an update |
| Q92527468 | The potential of neurofilaments analysis using dry-blood and plasma spots |
| Q64119505 | Vitamin D Supplementation as Add-on Therapy in Multiple Sclerosis-Balance between Benefit and Risk?: A Commentary on Vitamin D Supplementation in Central Nervous System Demyelinating Disease-Enough Is Enough |
Search more.